Does darolutamide combination therapy improve survival for metastatic hormone-sensitive prostate cancer?
Darolutamide is a next-generation androgen receptor inhibitor used to treat advanced prostate cancer. For men with metastatic hormone-sensitive prostate cancer (mHSPC), adding darolutamide to standard hormone therapy (androgen-deprivation therapy, or ADT) with or without chemotherapy has been shown to improve survival outcomes. Clinical trials demonstrate that darolutamide combination therapy significantly reduces the risk of death and delays disease progression.
What the research says
A large phase 3 trial (ARASENS) found that darolutamide plus ADT and docetaxel reduced the risk of death by 32.5% compared to placebo plus ADT and docetaxel (hazard ratio 0.68; 95% CI 0.57-0.80) 7. This survival benefit was consistent across subgroups, including patients with high- and low-volume disease 7. A systematic review and meta-analysis of 3 randomized clinical trials involving 3,483 patients confirmed that darolutamide combination therapy improves overall survival in mHSPC 1. The ARANOTE trial, which evaluated darolutamide plus ADT without chemotherapy, also showed a 46% reduction in the risk of radiological progression or death (hazard ratio 0.54; 95% CI 0.41-0.71) and a trend toward improved overall survival (hazard ratio 0.81; 95% CI 0.59-1.12) 6. Additionally, darolutamide combination therapy delayed pain progression and maintained health-related quality of life 3. A review of combination treatments for mHSPC highlights that triplet therapy (ADT plus an androgen receptor pathway inhibitor plus docetaxel) improves overall survival, with the ARASENS trial showing a hazard ratio of 0.68 8. Overall, the evidence strongly supports that darolutamide combination therapy improves survival in mHSPC.
What to ask your doctor
- Based on my disease volume (high or low), would darolutamide combination therapy be appropriate for me?
- What are the potential side effects of adding darolutamide to my current treatment?
- Should I receive darolutamide with ADT alone or with ADT plus docetaxel?
- How will my response to darolutamide be monitored over time?
- Are there any ongoing clinical trials for darolutamide that I might be eligible for?
This question is drawn from common patient questions about Urology and answered using cited medical research. We do not provide individualized advice.